Abstract 372P
Background
Post concurrent chemo-radiotherapy (CRT) response assessment in locally advanced head and neck squamous cell carcinoma (HNSCC) has been critical to decide further treatment. Morphological response assessment was challenging due to prevailing post-radiation changes. While, molecular response methods have been encouraging. Nonetheless, heterogeneity in various molecular criteria need further clarifications. This study aims to propose and evaluate effectiveness of a semi-quantitative molecular response criterion to predict recurrence and survival.
Methods
A five points HAN-MI-RADS criterion was proposed by the two ≥ 15 yrs experienced Nuclear Medicine physicians and PET/CT of locally advanced HNSCC patients (n-83) post CRT at 3 months were reanalyzed. Histopathology examination (HPE) at 3 months and HPE/clinical/ imaging outcome on follow-up was taken as standard for disease status. Diagnostic statistics, disease free survival (DFI) and overall survival (OS) were calculated. A comparison with Hopkins score was also done with ROC analysis.
Results
Metastasis was developed in 11/83 patients (13.3%) at 3 months evaluation. Of 72 patients, 39, 2 and 31 patients had complete response (Score 1, 2, 3A), equivocal response (score 3B), and partial response (Score 4, 5) as per HAN-MI-RADS. Per patient sensitivity, specificity, PPV, NPV and accuracy for predicting loco-regional disease up to one year and two years was 93.3%, 92.5%, 90.3%, 94.9%, 92.9% and 84.9%, 91.9%, 90.3%, 87.2%, 88.6% respectively. One year and two years DFI for each HAN-MI-RADS score showed statistically significant difference while it was not for OS. The ROC curve analysis showed significantly better disease outcome predictability of HAN-MI-RADS (AUC 0.884) than Hopkins (AUC 0.699).
Conclusions
A five points HAN-MI-RADS criterion was found promising for response assessment with less equivocal results and statistically significant higher AUC than Hopkins for loco-regional recurrence prediction. Further, prospective studies analysis with larger patients will prove its clinical validity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract